NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age

NCT02610348

CompletedNA

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions: Hepatitis B

Interventions: DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines, DTaP-HB-IPV and Pneumococcal polysaccharide vaccines

Countries: Thailand

Primary Objective: To describe the persistence of Hep B antibodies (Ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either Hexaxim®/Hexyon®/Hexacima® or Infanrix® hexa at 2, 4 and 6 months of age following Hep B vaccination at birth.

Eligibility overview

Sex: ALL

Age: 12 Months to 18 Months

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Subjects having received 4 Hep B doses in A3L12 (i.e. one dose at birth + three doses during study at 2, 4 \& 6 months of age)
* Subjects having participated in PNA19
* Subject's parents having given authorization to use serum collected in PNA19 for future research
* The initials, birth date, and gender of the subject are consistent between A3L12 and PNA19 databases
* Subjects for whom retention sera are of enough volume to allow a valid determination of the HBsAg antibody level.

Exclusion Criteria:

* Not applicable.

Locations (2)

Bangkok, Thailand
Khon Kaen, Thailand